Arsenic trioxide alone or with ATRA (Vesanoid) [tretinoin] for resistant hematologic malignancy

Trial Profile

Arsenic trioxide alone or with ATRA (Vesanoid) [tretinoin] for resistant hematologic malignancy

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2013

At a glance

  • Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Feb 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 05 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top